for about $487 million in cash as the drugmaker aims to bolster its arsenal of gene therapies that target a range of disabilities.
Shares of Akouos, which is developing gene therapies for sensorineural hearing loss, soared 84% to trade 40 cents above Lilly's offer price of $12.50 before the opening bell. The deal also includes a payment of $3 per share contingent on certain events related to drug trials and has the potential to increase the transaction size to $610 million, the companies said on Tuesday.
Eli Lilly has been striving to build its pipeline of gene therapies, following the acquisition of Prevail Therapeutics Inc for $1 billion last year.in a new research hub in Boston, Massachusetts earlier this year that focuses on developing gene therapies.Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli and Anil D'Silva
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: TMZ - 🏆 379. / 59 続きを読む »